FDA Approves First-Ever Treatment for Familial Chylomicronemia Syndrome (FCS)
Exciting news! The U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen), developed by Ionis, as the first-ever treatment for Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic condition that causes dangerously high triglyceride levels, increasing the risk of severe health complications–especially pancreatitis. This approval is a major milestone—not just for people with […]
FDA Approves First-Ever Treatment for Familial Chylomicronemia Syndrome (FCS) Read More »









